William Blair Increases Earnings Estimates for Genmab A/S
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
Morgan Stanley Remains a Hold on Genmab (GMAB)
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.
Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...
Genmab Stops Blood Cancer Treatment Development After J&J Won't License It
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
Fintel on MSN2d
William Blair Upgrades Genmab A (GMAB)
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
Genmab A/S (0MGB) Gets a Buy from Barclays
Barclays analyst Emily Field maintained a Buy rating on Genmab A/S (0MGB – Research Report) today and set a price target of DKK2,100.00. The ...
Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option
Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.
Nasdaq4d
Genmab Reveals J&J's Decision Not To Advance Hexabody-CD38, Shares Fall
(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
Genmab price target lowered to $45 from $50 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares.